The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
Abstract
Primary biliary cirrhosis (PBC) is a progressive cholestatic liver disease frequently leading to development of cirrhosis and its complications. Ursodeoxycholic acid (UDCA) is a beneficial medical therapy for patients with PBC. Improvement in some histological features, but not in histological stage, has been reported after 2 years of UDCA therapy. Thus, longer follow–up may be necessary to determine whether UDCA has a favorable effect on histological stage of disease and progression to cirrhosis. Our aim was to determine the long–term effects of UDCA therapy on histological stage and progression to cirrhosis in patients with PBC. Sixteen unselected patients with noncirrhotic PBC who had been on long–term UDCA therapy (13–15 mg/kg/d) for 6.6 ± 0.4 years (range, 5–9 years) were identified and their histological finding during treatment compared with that of 51 noncirrhotic patients with PBC who had received ineffective therapy (d–penicillamine [DPCA] or placebo) for 5.6 ± 0.07 years (range, 5–8 years). Histological stage was determined using the Ludwig classification. The rate of progression to cirrhosis (stage 4) was significantly less in the UDCA group than in the control group (13% vs. 49%P= .009). Although the overall rate of progression of histological stage was less in the UDCA group than in the control group (50% vs. 71%), this difference was not significant (P= .1). A marked improvement in liver biochemistries and Mayo risk score was noted in all patients during UDCA therapy; however, this improvement was not significantly different between patients who progressed and those who did not. In conclusion, long–term UDCA therapy appeared to delay the development of cirrhosis in PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Self-citationUrsodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Self-citationKaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
COMBES, B. (1995) · Hepatology · doi:10.1016/0270-9139(95)90294-5 · Cited by 268
Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis
Lindor, K., Therneau, T., Jorgensen, R., Malinchoc, M., & Dickson, E. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613058 · Cited by 228
Self-citation
Research works printed but not linked: 7
- Combes, 1995, Hepatology, 22, 759
- Emmond, 1996, Hepatology, 24, 168a
- Dickson, 1989, 10 Hepatology, 97, 1
- Kilmurry, 1996, Hepatology, 23, 1148
- Batts, 1996, Am J Gastroenterol, 91, 2314
- Lindor, 1995, Hepatology, 22, 1158
- Kaplan, 1987, Adv Inten Med, 32, 359
Cited by
Items 101–200 of 235
Liver Transplantation for Primary Biliary Cholangitis
Martin, E. F. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.014 · Cited by 24
Diagnosis and management of primary biliary cirrhosis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.979792 · Cited by 24
“Treatment with UDCA results in a slower rate of progression to cirrhosis: 13 versus 49% in a placebo group [133].”
BackgroundSelf-citationTreatment of primary biliary cirrhosis
Poupon, R. Y., & Poupon, R. E. (2000) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2000.0107 · Cited by 22
A brief review on prognostic models of primary biliary cholangitis
Chen, S., Duan, W., You, H., & Jia, J. (2017) · Hepatology International · doi:10.1007/s12072-017-9819-9 · Cited by 20
Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC)
Janmohamed, A., & Trivedi, P. J. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.002 · Cited by 21
Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States
Shahab, O., Sayıner, M., Paik, J. M., Felix, S. C., Golabi, P., & Younossi, Z. M. (2019) · Hepatology Communications · doi:10.1002/hep4.1314 · Cited by 21
“(10,11) UDCA is not a definitive cure, but treatment can slow disease progression and delay the need for liver transplantation.(12) Additionally, obeticholic acid, a farnesoid X receptor agonist, has been recently approved for patients with PBC with inadequate response to UDCA and for patients who are intolerant to UD…”
BackgroundHigh-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Smith, T. M., & Befeler, A. S. (2007) · Current Gastroenterology Reports · doi:10.1007/s11894-008-0021-z · Cited by 20
Roberts, S. B., Choi, W. J., Worobetz, L., Vincent, C., Flemming, J. A., Cheung, A., Qumosani, K. M., Swain, M. G., Grbic, D., Ko, H. H., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101168 · Cited by 33
Self-citationVariant Syndromes of Autoimmune Liver Diseases: Classification, Diagnosis and Management
Weiler‐Normann, C., & Lohse, A. W. (2016) · Digestive Diseases · doi:10.1159/000444472 · Cited by 21
Prognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis
Yamashita, Y., Umemura, T., Kimura, T., Joshita, S., Hirohara, J., Nakano, T., Komori, A., & Tanaka, A. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100662 · Cited by 22
Emerging novel treatments for autoimmune liver diseases
Tanaka, A. (2019) · Hepatology Research · doi:10.1111/hepr.13347 · Cited by 19
Primary biliary cirrhosis: From bench to bedside
Kouroumalis, E., & Notas, G. (2015) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v6.i3.32 · Cited by 21
Combination antiretroviral studies for patients with primary biliary cirrhosis
Lytvyak, E., Montano-Loza, A. J., & Mason, A. L. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.349 · Cited by 17
Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy
Douglass, A., Wallace, K., Koruth, M., Barelle, C. J., Porter, A. J., & Wright, M. C. (2008) · Hepatology International · doi:10.1007/s12072-008-9093-y · Cited by 19
“This compound is also given to patients with primary biliary cirrhosis and has been reported to reduce progression to cirrhosis [55].”
BackgroundZen, Y., Hübscher, S. G., & Nakanuma, Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00009-1 · Cited by 21
Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid
Abbas, G., & Lindor, K. D. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903493460 · Cited by 18
“In one study, the rate of histologic progression to cirrhosis was significantly less in the UDCA group than in the control group (13 vs 49%) [40].”
BackgroundSelf-citationNeuman, M. G., Cameron, R., Haber, J. A., Katz, G. G., & Blendis, L. M. (2002) · Liver International · doi:10.1046/j.0106-9543.2002.01640.x · Cited by 16
Mason, A. L., & Wasilenko, S. T. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.006 · Cited by 16
Liver transplantation in adults: Choosing the appropriate timing
Siciliano, M., Parlati, L., Maldarelli, F., Rossi, M., & Corradini, S. G. (2012) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v3.i4.49 · Cited by 22
Risk stratification and prognostic modelling in primary biliary cholangitis
Goet, J. C., Harms, M. H., Carbone, M., & Hansen, B. E. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.006 · Cited by 19
Primary biliary cirrhosis and liver transplantation
Akamatsu (2012) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2012.v1.2.66 · Cited by 26
The management of autoimmunity in patients with cholestatic liver diseases
Ali, A. H., Carey, E. J., & Lindor, K. D. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1095088 · Cited by 15
Self-citationTreatment of primary biliary cirrhosis
Szalay, F. (2001) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(01)00055-9 · Cited by 14
Clinical Studies With Silymarin: Fibrosis Progression Is the End Point
Schuppan, D., & Hahn, E. G. (2001) · Hepatology · doi:10.1002/hep.510330230 · Cited by 14
Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis
Levy, C., & Lindor, K. D. (2003) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-003-0010-0 · Cited by 14
Self-citationAn Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis
Burman, B. E., Jhaveri, M. A., & Kowdley, K. V. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.06.005 · Cited by 13
Purucker, E. A. (2001) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(01)00096-4 · Cited by 12
Ursodeoxycholic acid reduces increased circulating endothelin 2 in primary biliary cirrhosis
Dimoulios, P., Kolios, G. C., Notas, G., Matrella, E., Xidakis, C., Koulentaki, M., Tsagarakis, N. J., Kouroumalis, A., & Kouroumalis, E. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02307.x · Cited by 12
Lazaridis, K. N., & Lindor, K. D. (1999) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-999-0051-0 · Cited by 12
Self-citationManagement of primary biliary cirrhosis resistant to ursodeoxycholic acid therapy
Poupon, R. Y. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80438-9 · Cited by 12
Current Treatment Options for Primary Biliary Cholangitis
Wong, K. A., Bahar, R., Liu, C. H., & Bowlus, C. L. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.003 · Cited by 11
Hosonuma, K., Sato, K., Yanagisawa, M., Kakizaki, S., Takagi, H., Hirato, J., & Mori, M. (2013) · Gastroenterology Research and Practice · doi:10.1155/2013/168012 · Cited by 15
Management of primary biliary cirrhosis
Levy, C., & Lindor, K. D. (2003) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-003-0051-4 · Cited by 11
Self-citationThe treatment of primary biliary cholangitis: from shadow to light
Dražilová, S., Koky, T., Macej, M., Janíčko, M., Simkova, D., & Jarčuška, P. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241265782 · Cited by 16
“18 In another study, paired biopsies were taken after about 4 years of treatment.”
BackgroundUpdate on Emerging Treatment Options for Primary Biliary Cholangitis
Aguilar, M. T., & Chascsa, D. M. H. (2020) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s205431 · Cited by 11
Colestimide: The efficacy of a novel anion‐exchange resin in cholestatic disorders
Matsuzaki, Y. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02860.x · Cited by 11
Automated Enzymatic Mitochondrial Antibody Assay for the Diagnosis of Primary Biliary Cirrhosis
Jensen, W. A., Jois, J. A., Murphy, P., Giorgio, J. D., Brown, B., Rowley, M. J., & Mackay, I. R. (2000) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2000.107 · Cited by 10
Treatment of Primary Biliary Cholangitis
Liu, C.-H., & Bowlus, C. L. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.012 · Cited by 9
Primary biliary cholangitis and systemic sclerosis (Reynolds syndrome): A case–control study
David, C., Chaigne, B., Hollande, C., Terris, B., Cohen, P., Dunogué, B., Terrier, B., Sogni, P., Goulvestre, C., & Mouthon, L. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102842 · Cited by 10
Tsuji, K., Tamaki, N., Kurosaki, M., Mori, N., Takaki, S., Ohya, K., Mashiba, T., Ochi, H., Kobashi, H., Ogawa, C., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14172 · Cited by 8
Abbas, N., Smith, R. A., Lytvyak, E., Scraravaglio, M., Halliday, N., Almahroos, A., Eden, N., Lloyd‐Madden, D., Sharma, S., Ferguson, J., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70378 · Cited by 9
Recurrent nonviral liver disease following liver transplantation
Li, K., & Neuberger, J. (2009) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.09.16 · Cited by 8
Therapeutic advances for primary biliary cholangitis: the old and the new
Wang, L., Zhang, F., & Zhang, X. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000591 · Cited by 11
Pretransplant Evaluation and Liver Transplantation Outcome in PBC Patients
Mijić, M., Saric, I., Delija, B., Lalovac, M., Sobočan, N., Radetić, E., Martinčević, D., & Kanižaj, T. F. (2022) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2022/7831165 · Cited by 11
“Several trials have reported that UDCA is associated with significant improvement in liver function tests, improvement in histology, and prolonged transplant-free survival [3, 6, 9, 10].”
BackgroundUrsodeoxycholic acid production by Gibberella zeae mutants
Kollerov, V., & Donova, M. V. (2022) · AMB Express · doi:10.1186/s13568-022-01446-2 · Cited by 8
Long, L., Xue, C.-Q., Shi, J., Dong, J.-N., & Wang, L. (2015) · Hepatitis Monthly · doi:10.5812/hepatmon.29052v2 · Cited by 8
“(26) 21 16 UDCA (13 - 15 mg/kg/d) D-penicillamine (the dosage was unclear) 24 w AST, TBIL”
Alomari, M., Covut, F., Momani, L. A. A., Chadalavada, P. N., Hitawala, A. A., Young, M., & Romero‐Marrero, C. (2019) · JGH Open · doi:10.1002/jgh3.12223 · Cited by 9
Jiang, Z., Liu, X., Yuan, Z., He, H., Wang, J., Zhang, X., Gong, Z. L., Hou, L., Shen, L., Guo, F., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00189 · Cited by 9
Herold, C., Ganslmayer, M., Deynet, C., Hahn, E. G., & Schuppan, D. (2002) · Liver International · doi:10.1034/j.1600-0676.2002.01641.x · Cited by 8
Traboulsi, D., Kamińska, E., Barr, S. G., Hunter, C., & Mydlarski, P. R. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2018.04.016 · Cited by 7
“Overlap exists between limited systemic sclerosis and primary biliary cirrhosis (PBC); however, rare case reports document an association between morphea and PBC.1 Moreover, scleroderma-like tissue reactions are described in both solid-organ malignancies and plasma cell dyscrasias2; yet only 1 case report details an a…”
BackgroundInfluentialUrsodeoxycholic Acid for the Treatment of Liver Diseases
Wang, J.-Y., & Wu, S.-D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804274-8.00055-2 · Cited by 11
Fong, D. G., & Lindor, K. D. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)01032-7 · Cited by 7
Self-citationThe Discovery of Obeticholic Acid ( Ocaliva™ ): First‐in‐Class FXR Agonist
Pellicciari, R., Pruzanski, M., & Gioiello, A. (2018) · Wiley eBooks · doi:10.1002/9783527808694.ch8 · Cited by 12
Autorinnen/Autoren, & Collaborators (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2558-5204 · Cited by 10
Singh, A., Fritze, D. M., Mansouri, M., López, R., Poordad, F. F., Lawitz, E., Cigarroa, F. G., Halff, G. A., & Alkhouri, N. (2018) · Transplantation · doi:10.1097/tp.0000000000002501 · Cited by 6
“(Transplantation 2019;103:1191–1198) Transplantation TP TPA 0041-1337/18/10306-1191 Lippincott Williams & WilkinsHagerstown, MD 10.1097/TP.0000000000002501 Singh et al xxxJune xxxMonth2019 6 2018 LWW Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.<zdoi;10.1097/TP.0…”
BackgroundInfluentialAishima, S., KURODA, Y., Nishihara, Y., TAGUCHI, K., Yoshizumi, T., Taketomi, A., Maehara, Y., & Tsuneyoshi, M. (2006) · Hepatology Research · doi:10.1016/j.hepres.2006.07.008 · Cited by 6
Lohse, A. W., & Weiler‐Normann, C. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.032 · Cited by 6
Management of primary biliary cirrhosis: From diagnosis to end-stage disease
Lazaridis, K. N., & Lindor, K. D. (2000) · Current Gastroenterology Reports · doi:10.1007/s11894-000-0091-z · Cited by 6
Self-citationMilkiewicz, M., Kopycińska, J., Kempińska‐Podhorodecka, A., Haas, T. L., Bogdanos, D. P., Elias, E., & Milkiewicz, P. (2014) · Journal of Immunology Research · doi:10.1155/2014/921285 · Cited by 6
“Nevertheless, UCDA regulates the endogenous secretion of bile acid, reduces the cytotoxicity of endogenous bile acids, modulates the production of inflammatory cytokine, is protective against oxidative stress, and inhibits cell apoptosis [6] [7].”
BackgroundSurrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis
van Buuren, H. R., Lammers, W. J., Harms, M. H., & Hansen, B. E. (2015) · Digestive Diseases · doi:10.1159/000440759 · Cited by 6
Jamal, F., Elshaer, A., Alatout, M. H., Odeh, N. B., Youssef, A., Abo Abdullah, H., Elmasry, S., Shahin, T., Abdul Nabi, H., Worden, A. R., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13102335 · Cited by 6
“Several trials have shown that UDCA prolongs transplant-free survival and slows disease progression; however, it does not reliably control pruritus and fatigue [8,9].”
Autoimmune and Chronic Cholestatic Disorders of the Liver
Batts, K. P. (2009) · Elsevier eBooks · doi:10.1016/b978-141604059-0.50042-4 · Cited by 5
Self-citationThe timing of liver transplantation in primary biliary cirrhosis
Angulo, P., & Dickson, E. R. (2000) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2000.0110 · Cited by 5
Self-citationClark, V., & Levy, C. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-118-5_3 · Cited by 5
Methotrexate in the treatment of primary biliary cirrhosis: The hype and the hope
Angulo, P., & Dickson, E. R. (1999) · Gastroenterology · doi:10.1053/gast.1999.0029900492 · Cited by 6
Self-citationLevy, C., Lleo, A., Martins, A., Scaravaglio, M., Bowlus, C. L., Carbone, M., Corpechot, C., Couto, C. A., Hansen, B. E., Hirschfield, G. M., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.03.038 · Cited by 13
Pinyopornpanish, K., Chadalavada, P., Sarmini, M. T., Khoudari, G., Alomari, M., Padbidri, V., & Romero-Marrero, C. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002216 · Cited by 4
Treatment response in primary biliary cholangitis: The role of autoimmune hepatitis features
Mané, F., Cardoso, H., Liberal, R., Lopes, S., Pereira, P., Gonçalves, R., & Macedo, G. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2018.11.006 · Cited by 5
Kang, Y.-Z., Sun, X.-Y., Liu, Y., & Shen, Z. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i7.2236 · Cited by 4
Management of Patients with Primary Biliary Cirrhosis: A Practical Guide
Nishio, A., Neuberger, J., & Gershwin, M. E. (1999) · BioDrugs · doi:10.2165/00063030-199912030-00001 · Cited by 4
“effects of long term treatment with UDCA on survival.[73,74] It is recommended that UDCA be started in the”
BackgroundMilkiewicz, P., & Heathcote, J. (2006) · Wiley eBooks · doi:10.1002/9780470986981.ch21 · Cited by 4
Is primary biliary cirrhosis a risk factor for hepatic and extrahepatic malignancies
Deutsch, M. J. (2009) · Annals of Gastroenterology · Cited by 3
Cançado, G. G. L., Gomes, N. M. D. F., Couto, C. A., Cançado, E. L. R., Terrabuio, D. R. B., Villela‐Nogueira, C. A., Braga, M. H., Nardelli, M. J., Faria, L. C., Oliveira, E. M. G., et al. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002744 · Cited by 3
Dohmen, K., Tanaka, H., Haruno, M., & Aishima, S. (2016) · Journal of Gastroenterology and Hepatology Research · doi:10.17554/j.issn.2224-3992.2016.05.635 · Cited by 3
Liver Transplantation: Prevention and Treatment of Rejection
Cecilioni, L., Dagher, L., & Burroughs, A. K. (2004) · Wiley eBooks · doi:10.1002/9780470987025.ch36 · Cited by 3
Sherlock, F. S., & BSc, J. D. (2001) · Wiley eBooks · doi:10.1002/9780470986820.ch14 · Cited by 3
Shen, L., Lv, T., Li, S., Chen, S., Li, B., Zeng, X., Xiao, Q., Kong, Y., Wang, Y., Ma, H., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-025-02342-9 · Cited by 3
Sebode, M., Bantel, H., Baumann, U., Bufler, P., Demir, M., Dold, L., Keitel, V., Klein, R., Kremer, A. E., Jansen, P. L., et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2769-2475 · Cited by 2
Zen, Y., Hübscher, S. G., & Nakanuma, Y. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00009-0 · Cited by 3
Tanaka, A., Leung, P. S. C., Bowlus, C. L., & Gershwin, M. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_22 · Cited by 2
Approaches to the design of clinical trials for primary sclerosing cholangitis
Imam, M. H., Lindor, K. D., & Talwalkar, J. A. (2012) · Clinical Investigation · doi:10.4155/cli.12.75 · Cited by 2
Self-citationPoupon, R. Y. (2010) · EMC - Hépatologie · doi:10.1016/s1155-1976(10)46408-6 · Cited by 5
Liver Transplantation: Prevention and Treatment of Rejection
Pleguezuelo, M., Germani, G., & Burroughs, A. K. (2010) · Wiley eBooks · doi:10.1002/9781444314403.ch42 · Cited by 2
Martins, A., & Levy, C. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001076 · Cited by 3
Romeo, M., Nardo, F. D., Basile, C., Napolitano, C., Vaia, P., Martinelli, G., Gregorio, A. D., Puorto, L. D., Indipendente, M., Dallio, M., et al. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15120597 · Cited by 3
“Age and sex have been largely demonstrated to influence both response to treatment and long-term outcome of patients with PBC, thus enabling the inclusion of these variables into various risk stratification and prognostic models for PBC, as detailed below [132–134].”
Ali, A. H., Carey, E. J., & Lindor, K. D. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.908701 · Cited by 1
“For instance, in PBC, a significant correlation between improvements in hepatic enzymes/function panel and histological improvement with UDCA therapy exists [32].”
BackgroundSelf-citationBenign biliary conditions with increased risk of malignant lesions
Welle, C. L., Khot, R., Venkatesh, S. K., Paspulati, R. M., Ganeshan, D., & Fulcher, A. S. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04630-z · Cited by 1
“While there is no cure, early treatment with ursodeoxycholic acid has been shown to delay progression to cirrhosis [12, 13].”
Trivella, J. P., & Levy, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26710-9.00018-3 · Cited by 1
Primary Biliary Cholangitis: Its Science and Practice
Wang, L., Bowlus, C. L., Wang, F., & Gershwin, M. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-50168-0_8 · Cited by 2
Tanaka, A., & Gershwin, M. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00058-0 · Cited by 2
Ursodeoxycholic Acid in Liver Cirrhosis: A Chinese Perspective
Gao, W., Li, Z., Chu, H., Yuan, H., Hu, L., Yao, L., Zhang, L. R., Wang, W., Lin, R., & Yang, L. (2022) · Springer eBooks · doi:10.1007/978-981-19-2615-0_6 · Cited by 1
Gossard, A. A., & Lindor, K. D. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511547416.011 · Cited by 1
Self-citationRecurrence of the Original Disease
Neuberger, J. (2012) · doi:10.1002/9781444398441.ch33 · Cited by 1
Poupon, R. Y. (2010) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(10)70489-x · Cited by 1
Poupon, R. Y. (2010) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(10)54652-0 · Cited by 2
Examining the increased IgM production and ursodeoxycholic acid treatment in PBC
Lazaridis, K. N., & LaRusso, N. F. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.040 · Cited by 1
Gaya, D. R., McLay, A. L. C., Oien, K. A., Spooner, R. J., & Reilly, T. G. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.012013 · Cited by 1
Primary Biliary Cholangitis (Formerly Primary Biliary Cirrhosis)
Trivedi, P. J., & Hirschfield, G. M. (2019) · Wiley eBooks · doi:10.1002/9781119211419.ch38 · Cited by 1
Autoimmune Liver Diseases in Canterbury, New Zealand
Ngu, J. H. (2013) · Otago University Research Archive (University of Otago) · Cited by 2
Biotransformation of Bile Acids by Bacteroides sp. Strain T-40 Isolated from Human Microflora
Ogura, Y. (2007) · Institutional Repositories DataBase (IRDB)
Metadata
- Authors
- Angulo, P., Batts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, R. E., & Lindor, K. D.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Lindor, Keith D.
- Venue
- Hepatology
- Published
- 1999-03
- Volume
- 29
- Issue
- 3
- Pages
- 644-647
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1993958712
- Cited by
- 234
- References
- 24
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 7 · 2023: 1 · 2022: 10 · 2021: 2 · 2020: 5 · 2019: 11 · 2018: 15 · 2017: 12 · 2016: 7 · 2015: 12 · 2014: 7 · 2013: 7 · 2012: 10
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6028 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- primary biliary cirrhosis, ursodeoxycholic acid, histological progression, long-term treatment, Ludwig classification, D-penicillamine, Mayo risk score, cholestatic liver disease, liver histopathology
- MeSH terms
- Adult, Aged, Cholagogues and Choleretics, Female, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Middle Aged, Penicillamine, Time Factors, Ursodeoxycholic Acid, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.